FDA approves BromSite to treat inflammation, prevent pain in cataract surgery

The FDA has approved BromSite to treat postoperative inflammation and prevent ocular pain in patients who undergo cataract surgery, according to a press release from Sun Pharma. BromSite (bromfenac ophthalmic solution 0.075%) is the first NSAID approved by the FDA to prevent pain and treat inflammation in cataract surgery. The agent was developed by InSite Vision and is the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based formulation that can be used to improve solubility, absorption, bioavailability and residence time, according to the release.